Issue 5/2025
B. Atanasov, M. Stoykov
University Hospital „St. Marina“
Chronic prostatitis and chronic pelvic pain syndrom are some of the most common conditions in men under the age of 50. Current therapies for chronic prostatitis/chronic pelvic pain syndrome CP/CPPS are not highly effective and require further in-depth analysis and consideration of alternative strategies. In the past few years, interest in the use of phosphodiesterase type 5 inhibitors in the treatment of CP/CPPS has increased. Several clinical trials have shown that phosphodiesterase type 5 inhibitor preparations can lead to a sustained and marked reduction in symptoms in young men with CP/CPPS.
Kеy words: chronic prostatitis, chronic pelvic pain syndrome, phosphodiesterase type 5 inhibitors
Address for correspondence:
Prof. Dr. Boyan Atanasov
University Hospital „St. Marina“
Pleven, „Bulgarian Aviation“, Str.
e-mail: atanasovmd@yahoo.com